I review the present understanding of thromboembolic complications and their prevention in patients with nonrheumatic atrial fibrillation. Chronic atrial fibrillation carries an annual 3-6% risk of thromboembolic complications, which is 5-7 times greater than that of controls with sinus rhythm. Paroxysmal atrial fibrillation is associated with a lower risk of thromboembolic complications than chronic atrial fibrillation. Heart failure and systemic hypertension seem to be significant clinical risk factors for stroke in patients with atrial fibrillation, but disagreement persists, and, with few exceptions, subgroups at particular risk have not been convincingly identified. The risk of stroke in persons with thyrotoxic atrial fibrillation seems to be lower than believed previously. Clinical studies have shown that left atrial dilatation is a consequence of the duration of atrial fibrillation rather than a cause, but the relation of left atrial enlargement to stroke is uncertain. Cerebral blood flow may be reduced during atrial fibrillation but seems to increase after cardioversion to sinus rhythm. A high prevalence of silent cerebral infarction has been detected in patients with chronic atrial fibrillation, but there seems to be a low risk of silent cerebral infarction in persons with paroxysmal atrial fibrillation. The one prospective study published to date on stroke prevention in patients with nonrheumatic chronic atrial fibrillation showed that anticoagulation with warfarin significantly reduced the incidence of thromboembolic complications. (Stroke 1990;21:4-13)
A trial fibrillation (AF) is found in 0.4% of the adult population.
1 -2 Prevalence increases with age to a high of 2-4% in those >60 years old. 1 -3 In the Framingham Study 4 of 5,191 individuals, overall incidence of AF was 2%, rising sharply with age, but with no significant difference in incidence between the sexes. AF occurs in chronic and paroxysmal forms. 5 The causes are ischemic heart disease, hypertensive heart disease, thyrotoxicosis, chronic obstructive pulmonary disease, and rheumatic heart disease, among others. 6 Lone atrial fibrillation denotes AF without any detectable underlying heart disease. 6 -7 The prognosis for AF is a subject of rising interest due to the increase of elderly persons in the population, increased mortality among patients with AF versus patients with sinus rhythm, and the risk of thromboembolic complications.
2 -5 - 6 The primary aim of my review is to discuss several new aspects of thromboembolic complications in patients with AF, focusing on possible risk factors and the incidence of thromboembolic complications in those with chronic, paroxysmal, lone, and thyrotoxic AF. A second objective is to outline the significance of the left atrial dimension in the development of stroke and the importance of silent cerebral infarction. My final goal is to review the present knowledge of treatment with anticoagulants or aspirin to prevent thromboembolic complications in patients with AF. Future fields of clinical research in AF are also discussed.
Thromboembolic Complications in Atrial Fibrillation
The true distribution of chronic versus paroxysmal AF is difficult to establish because of the different methods used and the difficulties in verifying the paroxysms of AF, especially in outpatients. 8 Among 1,212 hospitalized patients with AF, paroxysmal AF occurred in 35%. 5 Two other hospital-based series found that 40% of 234 patients 9 and 33% of 414 patients 10 with AF had the paroxysmal form. In contrast, a study of life insurance records from 3,099 younger patients with AF found that 90% had the paroxysmal form, 11 a distribution similar to that found in studies of airmen. although the relative risk was higher for women. 16 The risk of stroke in patients with nonrheumatic chronic AF is increased more than fivefold over that in controls with sinus rhythm, as shown in the Framingham Study, 15 corresponding to a 4-5% annual incidence of stroke. The risk was increased 17-fold when the etiology of AF was rheumatic heart disease. This is in accordance with results from other studies of chronic A recent study of patients with nonrheumatic chronic AF (median age 74 years) found the annual incidence of thromboembolic complications to be 5.5% without protective treatments. 13 The British Whitehall and Regional Heart Studies found the total annual stroke incidences to be lower, 1.5% and 0.4%, respectively. 20 However, the relative risks were 6.9 and 2.3, respectively, in the two studies, close to the 5.6 found in both the Framingham Study 15 and the study by Tanaka et al. 19 The two British studies investigated a total of 111 men with nonrheumatic chronic AF aged 40-69 years at entry, corresponding to an approximate mean age of 55 years. The incidence of rheumatic heart disease has declined during the past decades, 9 -14 -20 -21 but the magnitude of the problem of stroke in AF is considerable because so many elderly patients have AF. 6^10 Thus, approximately 15-20% of all ischemic strokes are attributed to AF; that is, cardiogenic embolism is assumed to be the cause. 22 ' 23 The risk of stroke in patients with AF seems to be highest during the first months after the initial diagnosis of AF or immediately after a transition from paroxysmal to chronic AF. 25 This clustering of cerebrovascular complications should be taken into consideration when evaluating patients with AF for stroke prevention. However, some patients in retrospective 22 and prospective 25 studies had a diagnosis of stroke at the time of the initial diagnosis of AF; that is, it was difficult to establish whether AF was the consequence or the cause of a stroke. However, reevaluation of data from the Framingham Study still suggested a clustering of stroke during the first months after the initial diagnosis of AF. 25 ' 26 Distinct clusterings of stroke occurrence were found at the time of the initial diagnosis in 426 patients with paroxysmal AF as well as immediately after the arrhythmia became chronic, which occurred in 33% of the patients. 24 This implies that a clustering of stroke is in fact present since the patients with transition to chronic AF had the diagnosis of paroxysmal AF established before their stroke. However, in two other studies, stroke occurred at a fairly constant rate, 13 -20 which for at least one study could be explained by the fact that patients with AF and recent stroke were not enrolled; secondly, it was often difficult to establish how long AF had been present before the study. 13 
Risk Factors for Stroke in Chronic Atrial Fibrillation
In a reevaluation of data from the Framingham Study, 25 AF by itself, systolic blood pressure, age, the presence of ischemic heart disease, and the presence of congestive heart failure were independent risk factors for stroke, although it is not entirely clear whether the multifactorial analysis comprised all strokes or only those in the 59 patients with AF. However, two other reports from the same study failed to show any specific relevance of ischemic heart disease and congestive heart failure when comparing AF patients with and without stroke. 15 - 27 Flegel et al 20 found only hypertension to be important, with age and ischemic heart disease of no significance regarding the risk of stroke in patients with AF. Another study found rheumatic heart disease to be the only relevant risk factor for stroke. Congestive heart failure during the course of AF tended to be a risk factor, although not a significant one.
14 A study comparing stroke patients with and without AF found hypertension and ischemic heart disease to be nonsignificant and congestive heart failure to be a significant risk factor for stroke. 28 Preliminary data from the Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK) Study suggest that previous myocardial infarction is more prevalent in patients with thromboembolic events. Age, sex, heart failure, hypertension, diabetes, thyrotoxicosis, smoking, and chest pain were not significant (P. Petersen, G. Boysen, J. Godtfredsen, B. Andersen, unpublished data). Although congestive heart failure or hypertension were risk factors in several studies, the overall results conflict, probably because of the relatively small sample sizes. Thus, there is reason to look for other risk factors for stroke in patients with AF and to combine the data from ongoing studies. 23 Lavy et al 29 found cerebral blood flow to be less in patients with AF than in controls with sinus rhythm. Another study of nine patients found that decreased cerebral blood flow during chronic AF normalized after electrical cardioversion to sinus rhythm. 30 Thus, reduced cerebral blood flow could contribute to the development of stroke in persons with AF, but studies of more patients are needed.
The concentration of atrial natriuretic peptide is elevated during AF and normalizes after sinus rhythm is obtained. 31 Atrial natriuretic peptide increases hematocrit, 32^3 as do paroxysms of AF. 34 Chabrier et al 35 found atrial natriuretic peptide receptors in the microvessels of the brain, and although the importance of this finding is unknown, there might be a relation between elevated atrial natriuretic peptide concentration, decreased cerebral blood flow, and the occurrence of cerebrovascular complications in patients with AF. 30 Studies relating the left atrial diameter to stroke risk have yielded conflicting results. It is accepted that the left atrium is dilated in persons with AF, but whether left atrial enlargement is a cause or a consequence of the arrhythmia is under debate. Takahashi et al 36 found that the left atrial dimension showed a stepwise and significant increase when comparing normal subjects, patients without AF who had hypertension or ischemic heart disease, patients with paroxysmal AF and nonrheumatic chronic AF, and patients with rheumatic chronic AF. These authors pointed out that it seems unlikely that the left atrium should be dilated by infrequent paroxysms of AF of relatively short duration, suggesting that left atrial enlargement could possibly be a cause rather than a consequence of AF. A recent report 37 found a significant difference between left atrial dimension in sinus rhythm and chronic AF of short and long duration as well as a significant increase in left atrial dimension in chronic AF of both short and long duration after 6 months of follow-up. This shows that AF contributes to the enlargement of the atria, although it cannot be ruled out that this enlargement of the atria sometimes precipitates the development of AF. Similar results were obtained by Keren et al 38 and Presti et al, 39 and the results are indirectly supported by the success of electrical cardioversion therapy, which is related to the duration of AF and the degree of left atrial enlargement. 40 The finding that the left atrial dimension increases with the duration of AF may contribute to the decision to use electrical cardioversion therapy, especially when the duration of AF is unknown. 37 Moss 41 noted that "large atria are more likely to embolize than small ones." Thus, Caplan et al 42 found that left atrial enlargement may convey additional risk of stroke in persons with AF; 90% of 20 stroke patients with AF had enlarged left atria compared with 20% of 20 controls with AF without stroke. However, the duration of AF was not defined, and the retrospective nature of this study has been criticized. 43 A preliminary study 44 suggests that left atrial size in persons with AF is not a reliable predictor of stroke in comparing patients matched for age, sex, cardiomegaly, and duration, cause, and intermittency of AF. Ruocco and Most 45 and Wiener 46 also found that left atrial size was not significant in determining the risk of an embolic event in patients with AF. This issue is of great clinical importance, but conclusions regarding its applicability can be defined only by prospective studies of left atrial size prior to stroke. 43 The studies above used echocardiography to determine left atrial size. Threedimensional measurements of the volume of the atria and measurements of the transmitral diastolic blood flow by Doppler techniques and evaluation by scintigraphic techniques or computed tomography (CT) may more accurately predict thrombus formation and embolic risk in patients with AF. chronic AF or sinus rhythm. 10 It has, however, been suggested that paroxysmal AF carries a significant risk of stroke 51 and that treatment with oral anticoagulants should be considered. 52 In a retrospective study of 94 patients (80% men) with paroxysmal AF, 9 six cerebrovascular complications were noted, but no exact data were available about incidence rate. As follow-up was several years, it is likely that the annual frequency of stroke was low. It was not stated whether the events occurred before or after transition to chronic AF, which occurred in 19 of 75 patients (25.3%) with an observation period of more than 1 year. The onset of the first paroxysm had its peak incidence occurred between the ages of 50 and 69 years. Treseder et al 10 retrospectively investigated 414 elderly inpatients, 276 (40% men) with chronic AF and 138 (46% men) with paroxysmal AF, with a mean age of approximately 80 years in both groups. These authors found a significantly lower risk of stroke in the group with paroxysmal AF. A retrospective study of 426 patients (50% men) found the incidence of embolic complications during paroxysmal AF to be 2%, but after transition to chronic AF the incidence rose to 5%. 24 The rate of transition to chronic AF was 33%, with a median time to transition of 34 months. Median age at the onset of AF was 63 years in patients with and 68 years in those without transition. Important factors in the incidence of embolic complications and mortality were determined using Cox's regression model; Table 1 shows that only the occurrence of chronic AF was significantly related to the incidence of embolic complications. However, as the transition from paroxysmal to chronic AF depends on etiology (i.e., rheumatic heart disease) but not on sex or age (Table 2) , an indirect interaction between etiology and the incidence of embolic complications is likely. Table 3 shows that only age and the occurrence of embolism were important factors in mortality. Surprisingly, the number of paroxysms of AF was of no significance in the risk of embolization. The number of paroxysms of AF is probably underestimated in a retrospective study, but this does not change the fact that few embolic complications occurred. That paroxysmal AF is associated with a lower risk of embolization than chronic AF is supported by a recent study by Wiener 46 who found that chronic AF was the only clinical factor that separated AF patients with emboli from those without. Echocardiographic assessment did not distinguish between these patients.
The above studies all found the risk of embolic complications in patients with paroxysmal AF to be lower than that in patients with chronic AF. This does not seem to be explained by difference in age or underlying etiologies, 910 the only important factor being transition to chronic AF. 24 It is therefore possible that more intensive treatment of patients with paroxysmal AF with antiarrhythmic agents may postpone the development of chronic AF and thereby reduce their risk of stroke, but future studies are needed to show whether this is true. 24 Even when the low risk of embolization in patients with paroxysmal AF is considered, the risk seems higher than that found in epidemiologic series of age-matched patients without AF. 24 However, the above studies were hospital-based, the patients probably had more atherosclerosis than the controls with sinus rhythm, 10 and one study also included peripheral embolization. 24 No studies of stroke prevention in patients with paroxysmal AF are available, and considering their relatively low incidence of embolic complications, such a study will require many patients to show any effect of treatments.
Lone Atrial Fibrillation
The reported prevalence of lone AF among AF patients varies from 0.5% to 30%, probably reflecting different diagnostic criteria and methods employed rather than its true prevalence. 6 In his hospital-based series, Godtfredsen 5 found a prevalence of lone AF in patients with paroxysmal AF of 5% versus 0.6% in those with chronic AF, which is in accordance with the data from Kopecky et al. 53 Other authors report prevalences as high as 25% in patients with paroxysmal AF 9 and 25-31% in those with chronic AF.
-4
The risk of thromboembolic complications in patients with lone AF varies to a great extent, probably due to the above problems. Second, all estimates of stroke risk in patients with lone AF are based on relatively small numbers and therefore are encumbered with wide confidence limits. In a study of 97 patients with lone AF (80% men, mean age 44 years), the majority of whom had paroxysmal AF, a very low risk of stroke was found. 53 Close et al 54 investigated 86 patients with chronic lone AF (86% men, mean age 54 years); none suffered a Systemic embolic complication during a follow-up of approximately 8 years. A low risk of embolization in persons with paroxysmal lone AF is indirectly supported by a life insurance record study, in which mortality among persons with paroxysmal lone AF was found to be normal. 11 A slightly lower annual excess death rate was found in persons with chronic lone AF than in those with chronic AF having any associated underlying disease (excluding mitral stenosis), but the 5-year survival was almost identical. In contrast, the Framingham Study 4 -55 found that chronic lone AF was associated with a risk of stroke approximately four times that found for age-and sex-matched controls with sinus rhythm. The Framingham Study reported on 32 men and 11 women with lone AF with a mean age of approximately 70 years; that is, those patients were older than the persons in the studies above. The association between lone AF and stroke seemed to be similar between the sexes. However, the epidemiologic methods and the diagnostic criteria employed in the Framingham Study have been debated, 51 and some patients were probably classified as having chronic lone AF although an underlying heart disease, and in some cases thyrotoxicosis, may have been present. Accordingly, the prevalence of lone AF was 11%, 55 more than that found in other studies of chronic AF. 9 Thus, it is difficult to know the true risk of thromboembolic complications in persons with lone AF. However, younger patients with paroxysmal or chronic lone AF seem to have a low risk of stroke. The incidence of stroke in elderly patients with chronic lone AF appears to be increased, but further studies are needed, 56 and in particular, it seems warranted to use uniform diagnostic criteria concerning the underlying etiologies of AF. In patients with lone AF, no studies of anticoagulants or aspirin for stroke prevention are available, although treatment with anticoagulants has been suggested. 57 
Thyrotoxic Atrial Fibrillation
AF develops in 10-15% of patients with thyrotoxicosis and is most common in patients >60 years old, reflecting an age-related reduction in the threshold for the development of AF. 58 The clinical diagnosis of thyrotoxicosis is not always obvious in elderly patients, in whom AF may be the dominant feature. 58 - 60 The prevalence of thyrotoxicosis in patients with AF is 2-5%. patients with thyrotoxic AF, 62 - 65 and anticoagulants have been recommended for such patients. 58 -66 This is contrary to older studies in which the rarity of embolization in patients with thyrotoxic AF was commented upon. 67 
'
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A study by Staffurth et al, 62 in which 26 episodes of arterial embolism were found in 262 patients with thyrotoxic AF, included no control group. The study of Yuen et al 63 included 210 patients with thyrotoxicosis; 21 had AF and five of these 21 had systemic emboli, but no comparisons were made with a control group. Hurley et al 64 found eight arterial embolic complications in 68 patients with thyrotoxic AF, but insufficient data were provided on the 311 patients with thyrotoxicosis and sinus rhythm. Bar-Sela et al 65 found 12 embolic complications in 30 patients with thyrotoxic AF and no episodes in 112 patients with sinus rhythm; however, the mean ages in the AF and sinus rhythm classes were markedly different (56 and 39 years, respectively). The results of these studies indicate that thyrotoxic AF is associated with a high risk of embolization. This contrasts with the findings from a retrospective study, in which 610 thyrotoxic patients were investigated. 69 A total of 91 patients had AF (14.9%), with the highest frequency occurring in the elderly patients (Table 4) . A total of 59 patients (13 had AF) were excluded from the analysis of embolic events due to a follow-up time of < 1 year (n=57) or to current treatment with anticoagulants (n=2). In 46% of the remaining 78 AF patients, sinus rhythm developed after treatment of thyrotoxicosis, with the highest frequency in the younger patients (Table 4) . Table 5 shows the events during the first year, and Table 6 shows that only age was a significant risk factor for cerebrovascular complications. The incidence of cerebrovascular events in thyrotoxic AF of approximately 6% ( 61 That a significant difference in the occurrence of events between AF patients and those with sinus rhythm was not found can be explained by the relatively small number of AF patients. Further, the patients with sinus rhythm had a higher incidence of cerebrovascular complications than is expected from epidemiologic series for patients without thyrotoxicosis or AF. 69 However, the study could not confirm thyrotoxicosis as an etiology of AF as a significant risk factor for embolization compared with other etiologies of AF.
The present knowledge of the incidence of thromboembolic events in patients with thyrotoxic AF implies that the risk of embolization is approximately the same as for other etiologies of AF. A preliminary report by Norrving and Nilsson   70 detected a high frequency of silent cerebral infarction in patients with AF and cerebral embolism. This subject was investigated in a controlled study, in which 30 elderly outpatients with chronic AF of > 1 year's duration and 30 age-and sex-matched controls with sinus rhythm and no history of cerebrovascular disease were examined with CTJ 1 Fourteen AF patients had abnormal CT scans, with areas of low density sharply demarcated from surrounding tissue compared with such GT scans in eight patients with Significance assessed using logistic regression methods.
Silent Cerebral Infarction in Atrial Fibrillation
sinus rhythm. This difference in prevalence of abnormal CT scans was not significant, but the number of abnormal areas was significantly higher in the AF (39 lesions) than in the control (16 lesions) group ( Figure  1 ). There was no correlation between presence of low-density lesions and age, independent of rhythm disturbance. Most of the AF patients had atherosclerotic and/or hypertensive heart disease, whereas the controls considered themselves healthy. However, there was no significant difference in mean arterial blood pressure between the groups, and the controls probably had some degree of clinically silent atherosclerosis. These findings are supported by a recent preliminary study 72 and a study by Kempster et al, 73 who retrospectively investigated patients with chronic AF presenting with symptoms of cerebral ischemia.
A significantly higher prevalence of silent cerebral infarction was found in patients with chronic AF than in controls with sinus rhythm, although hypertension and diabetes were more common in the control group. As all subjects presented with cerebral ischemia, the degree of atherosclerosis in the two groups was probably the same. This does not exclude hypertension and generalized atherosclerosis as coexisting factors important in the occurrence of low-density areas on CT scans in patients with chronic AF. However, if these factors are of significance, it underscores the magnitude of this problem as most AF patients have systemic hypertension and/or atherosclerotic heart disease. More studies are, however, needed in patients with lone AF, that is, those without hypertension and known atherosclerosis, and in patients with sinus rhythm, hypertension, and atherosclerosis.
Few data are available from patients with paroxysmal AF. One study compared the prevalence of cerebral low-density areas on CT scans in 30 outpatients with paroxysmal AF and 30 age-and sexmatched controls with sinus rhythm without cerebrovascular disease and found no significant difference. 74 The number of subjects was relatively small and, accordingly, it cannot be ruled out that the true risk of cerebral low-density areas on CT scans would be increased by a factor of two or three, assuming a 10% risk in the controls. 74 The occurrence of cerebral abnormalities in these controls was lower than that from the study of Petersen et al, 71 but these controls were nearly 10 years younger than the others. A preliminary study by Sasaki et al 75 found a lower prevalence of silent cerebral infarction among patients with paroxysmal AF than in those with chronic AF, thus supporting the impression that the former is associated with a lower risk of cerebral damage than the latter.
Although the cerebral low-density areas on the CT scans were asymptomatic per definition, they might be important regarding cognition in elderly people. 2376 However, even if several studies find an increased prevalence of cerebral low-density areas on CT scans of AF patients, this new field of research needs more studies, with particular focus on the risk of developing clinically overt cerebrovascular disease.
Prevention of Embolism in Atrial Fibrillation
Stroke prevention in patients with AF has been discussed for several decades, in patients with rheumatic AF, 1718 but due to methodologic problems, the clinical interpretation of these studies is difficult to outline. Some authors have recommended oral anticoagulation for all patients with AF. 52 Other authors have suggested anticoagulation for subgroups, including patients with recurrent stroke, rheumatic AF, thyrotoxic AF, patients with large atria, and even patients with lone AF.41.57,66,78 j n patients with recurrent stroke, which seems to occur with a frequency of 15-20% within the first year alone, 23 only one prospective study of prophylactic anticoagulation is available, but those results were not conclusive. 78 In a retrospective study of 134 patients with nonrheumatic AF, emboli occurred in 5.9%/yr among patients who were without anticoagulation, compared with only 0.7%/yr among those treated with anticoagulants. 79 Recently, our group published prospective data from 1,007 outpatients with nonrheumatic chronic AF (median age 74.2, range 38-91 years). 13 The patients were randomized to treatment with warfarin, 75 mg aspirin/day, or placebo to evaluate the effect of treatment on the occurrence of thromboembolic complications. Anticoagulation therapy was conducted openly using Normotest (NycoMed AS, Oslo, Norway) with a therapeutic range of 4.2-2.8 (International Normalized Ratio) 80 ; the aspirin and placebo arms were double-blind. The patients were followed by the same investigator at scheduled intervals for 2 years. The primary end point was a thromboembolic complication, that is, transient cerebral ischemia, stroke, embolism to the viscera or to the extremities. A total of 20 thromboembolic complications was noted in the aspirin group, not significantly different from the 21 events in the placebo group. Five cerebrovascular complications were recorded in the warfarin group ( Table 7) . The difference in frequency of events in the three groups was statistically significant, even when adjusted for interim analysis. Moreover, only two of the five strokes occurred during adequate anticoagulation. Two patients had strokes after temporary cessation of anticoagulant treatment due to surgical intervention or evaluation of hematuria, and one patient had a stroke on the day of randomization, that is, before anticoagulant treatment was begun. Thus, a total of 46 patients had thromboembolic events (median age 73.7, range 38-85 years). The occurrence of thromboembolism increased with the duration of AF, with no evidence of a specific vulnerable period. The yearly incidence of events was 2.0% among patients receiving warfarin (95% confidence limits 0.6-4.8%) and 5.5% among those receiving either aspirin or placebo (95% confidence limits 2.9-9.4%). The number of thromboembolic events occurring after cessation of treatment were six, one, and four in the three Total no. of events groups, respectively (/?>0.10). Intention-to-treat analysis of all thromboembolic complications (including those in patients receiving treatment and in those who withdrew) gave a probability value of 0.056 in favor of warfarin (Figure 2 ). Vascular mortality was significantly lower during anticoagulation than during treatment with aspirin or placebo; however, intention-to-treat analysis of ah" deaths, including the patients who withdrew, showed no difference in either vascular or total mortality.
The study could be criticized because the anticoagulation therapy was conducted openly. However, the end points were well-defined thromboembolic complications manifesting most often as acute, severe deficits and subsequent hospital admission. Moreover, the risk of ignoring an end point was even lower during anticoagulation than during treatment with aspirin or placebo as the former patients were followed more intensively than the latter. Of 2,546 eligible patients, only 1,007 participated ( Figure 2 ). Among the 1,539 patients excluded, more than half refused to participate in a randomized trial. In the future, however, it could be expected that more outpatients will accept and continue treatment with anticoagulants. One fatal bleeding complication was seen during anticoagulation therapy. However, severe bleeding complications during the study were few, and in nine patients (43%) bleeding complications were ascribed to underlying malignant or inflammatory disease.
Future Aspects of Studies on Stroke in
Atrial Fibrillation We found a beneficial effect of warfarin for prevention of stroke in patients with AF. However, two important questions that remain are the length of time patients should be anticoagulated and whether any risk factors for stroke could be identified. The treatment time in the above study was 2 years so that no answer can yet be given as to whether anticoagulation for longer periods is desirable. Nor could we identify a particularly efficacious period for anticoagulation. Studies on the cost-benefit ratio of long-term anticoagulation are needed. A risk factor analysis, while desirable, would require more patients than were included in the above study. It is therefore important that the several studies in progress 23 be finished to pool the data to find answers to these problems. More studies on the prevalence and natural history of silent cerebral infarction are also warranted, as are studies of cerebral blood flow, left atrial dimension, and coagulation and fibrinolytic functions in patients with AF. It may then be possible to select patients at high risk of stroke for protective treatments.
